Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 715-724

  Fischer, James H ^a   Sarto, Gloria E ^b   Habibi, Mitra ^a   Kilpatrick, Sarah J ^c,f   Tuomala, Ruth E ^d   Shier, Janice M ^e,g   Wollett, Lori ^b   Fischer, Patricia A ^a   Khorana, Kinnari S ^a,h   Rodvold, Keith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^h Gilead Scientific Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ABDOMINAL CRAMP; ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD LEVEL; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG MEGADOSE; ETHNICITY; FEMALE; GESTATIONAL AGE; HUMAN; INFECTION; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VOMITING;

ADOLESCENT; ADULT; AREA UNDER CURVE; AZITHROMYCIN; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVES, ORAL; ETHNIC GROUPS; FEMALE; GESTATIONAL AGE; HUMANS; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

EID: 84856068359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00717-11     Document Type: Article

References (55)

1. al-Banna MK, Kelman AW, Whiting B. 1990. Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokinet. Biopharm. 18:347-360. (Pubitemid 20327531)
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
3. Amsden GW, Gregory TB, Michalak CA, Glue P, Knirsch CA. 2007. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am. J. Trop. Med. Hyg. 76:1153-1157. (Pubitemid 351837883)
4. Amsden GW, Nafziger AN, Foulds G. 1999. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob. Agents Chemother. 43:163-165. (Pubitemid 29069218)
5. Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. 2000. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J. Clin. Pharmacol. 40:1522-1527.
6. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44:989-1008. (Pubitemid 41356388)
7. Andrade SE, et al. 2004. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol. 191:398-407. (Pubitemid 39178690)
8. Asakura E, et al. 2004. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur. J. Pharmacol. 484:333-339. (Pubitemid 38117227)
9. Ballow CH, Amsden GW, Highet VS, Forrest A. 1998. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers. Clin. Drug Invest. 15:159-167. (Pubitemid 28101496)
10. Bertrand J, Comets E, Laffont CM, Chenel M, Mentre F. 2009. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J. Pharmacokinet. Pharmacodyn. 36:317-339.
11. Cao J, et al. 2001. Differential regulation of hepatic bile salt and organic anion transporters in pregnant and postpartum rats and the role of prolactin. Hepatology 33:140-147. (Pubitemid 32016896)
12. Cao J, Stieger B, Meier PJ, Vore M. 2002. Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy. Am. J. Physiol. Gastrointest. Liver Physiol. 283:G757-G766. (Pubitemid 34920366)
13. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
14. Cooper WO, et al. 2009. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr. Perinat. Epidemiol. 23:18-28.
15. Danesi R, et al. 2003. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J. Antimicrob. Chemother. 51:939-945. (Pubitemid 36503427)
16. D'Argenio D, Schumitzky A. 1997. ADAPT II user's guide. Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, CA.
17. D'Argenio DZ. 1981. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm. 9:739-756. (Pubitemid 12184821)
18. DuBois D, DuBois EF. 1916. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17:863-871.
19. Duffull S, Waterhouse T, Eccleston J. 2005. Some considerations on the design of population pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 32:441-457. (Pubitemid 41738435)
20. Ehnhage A, Rautiainen M, Fang AF, Sanchez SP. 2008. Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis. Int. J. Antimicrob. Agents 31:561-566.
21. He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. 2009. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol. Rep. 61:843-850.
22. Heikkinen T, Laine K, Neuvonen PJ, Ekblad U. 2000. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG 107:770-775. (Pubitemid 30311914)
23. Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. 2003. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob. Agents Chemother. 47:2770-2774. (Pubitemid 37040246)
24. Hodge LS, Tracy TS. 2007. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin. Drug Metab. Toxicol. 3:557-571. (Pubitemid 351324964)
25. Jamieson DJ, Theiler RN, Rasmussen SA. 2006. Emerging infections and pregnancy. Emerg. Infect. Dis. 12:1638-1643. (Pubitemid 44674237)
26. Janmahasatian S, et al. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44:1051-1065. (Pubitemid 41356391)
27. Jonsson EN, Wade JR, Karlsson MO. 1996. Comparison of some practical sampling strategies for population pharmacokinetic studies. J. Pharmacokinet. Biopharm. 24:245-263. (Pubitemid 26300487)
28. Kastrissios H, Ratain MJ. 2001. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest. 19:57-64. (Pubitemid 32233803)
29. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. 1972. Indices of relative weight and obesity. J. Chronic Dis. 25:329-343.
30. Lassus A. 1990. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J. Antimicrob. Chemother. 25(Suppl. A):115-121. (Pubitemid 20043957)
31. Lee PI. 2001. Design and power of a population pharmacokinetic study. Pharm. Res. 18:75-82. (Pubitemid 32299625)
32. Leslie KK, et al. 2000. Estrogens in intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 95:372-376. (Pubitemid 30100502)
33. Lucchi M, et al. 2008. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. J. Antimicrob. Chemother. 61:884-891. (Pubitemid 351426075)
34. Luke DR, Foulds G. 1997. Disposition of oral azithromycin in humans. Clin. Pharmacol. Ther. 61:641-648. (Pubitemid 27279925)
35. McGready R, et al. 2003. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. 59:553-557. (Pubitemid 37363567)
36. Metropolitan Life Insurance Company. 1983. Table of desirable body weights and heights. Metropolitan Life Insurance Company, New York, NY.
37. Muto C, Liu P, Chiba K, Suwa T. 2011. Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J. Antimicrob. Chemother. 66:165-174.
38. Nedelman JR. 2005. On some "disadvantages" of the population approach. AAPS J. 7:E374 -E382.
39. Ohman I, Luef G, Tomson T. 2008. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 17:199-202.
40. Paris R, et al. 2008. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J. Chemother. 20:77-86. (Pubitemid 351428667)
41. Parke J, Holford NH, Charles BG. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29. (Pubitemid 29125558)
42. Patel KB, et al. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40:2375-2379. (Pubitemid 26328049)
43. Pennell PB, et al. 2004. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62:292-295. (Pubitemid 38167143)
44. Pfizer. 2010. Zithromax (azithromycin tablets and azithromycin for oral suspension) U.S. prescribing information. Pfizer Laboratories, New York, NY.
45. Piscitelli SC, Danziger LH, Rodvold KA. 1992. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. 11:137-152.
46. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. 2007. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 30:213-221. (Pubitemid 47126817)
47. Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD. 2003. Maternal and transplacental pharmacokinetics of azithromycin. Am. J. Obstet. Gynecol. 188:714-718. (Pubitemid 36332439)
48. Ribbing J, Jonsson EN. 2004. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J. Pharmacokinet. Pharmacodyn. 31:109-134. (Pubitemid 38932393)
49. Ripa S, Ferrante L, Prenna M. 1996. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. Chemotherapy 42:402-409. (Pubitemid 26379928)
50. Salman S, et al. 2010. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob. Agents Chemother. 54:360-366.
51. Sarkar M, Woodland C, Koren G, Einarson AR. 2006. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 6:18.
52. Shepard RM, Duthu GS, Ferraina RA, Mullins MA. 1991. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J. Chromatogr. 565:321-337.
53. Sugie M, et al. 2004. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob. Agents Chemother. 48:809-814. (Pubitemid 38280329)
54. Trauner M, et al. 1997. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255-264. (Pubitemid 27281782)
55. Yano Y, Beal SL, Sheiner LB. 2001. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check.J. Pharmacokinet. Pharmacodyn. 28:171-192.